5 December 2006. Moscow – JSC Pharmstandard announces its audited financial results for 2004 and 2005 and reviewed financial results for H1 2006 in accordance with International Financial Reporting Standards (IFRS).
Key financial indicators
|
|
6 months comparison[1] |
Year to year comparison[2] |
|
RUR thousand |
6months 2006 |
6months 2005 |
Variance % |
2005 |
2004 |
Variance % |
|
Sale of goods |
2 916 686 |
2 417 194 |
21% |
5 684 824 |
3 945 684 |
44% |
|
Pharmaceutical products |
2 314 878 |
1 926 723 |
20% |
4 635 033 |
3 901 900 |
19% |
|
% of total sales |
79,4% |
79,7% |
|
81,5% |
98,9% |
|
|
Medical equipment and disposables |
549 048 |
462 104 |
19% |
1 011 120 |
0 |
- |
|
% of total sales |
18,8% |
19,1% |
|
17,8% |
0,0% |
|
|
Other sales |
52 760 |
28 367 |
86% |
38 671 |
43 784 |
(12%) |
|
% of total sales |
1,8% |
1,2% |
|
0,7% |
1,1% |
|
|
Gross profit |
1 683 704 |
1 206 632 |
40% |
3 177 722 |
1 725 703 |
84% |
|
% of total sales |
57,7% |
49,9% |
|
55,9% |
43,7% |
|
|
SG&A expenses |
685 703 |
666 648 |
3% |
1 512 778 |
1 053 596 |
44% |
|
% of total sales |
23,5% |
27,6% |
|
26,6% |
26,7% |
|
|
Profit before income tax |
896 523 |
416 775 |
115% |
1 443 697 |
437 315 |
230% |
|
% of total sales |
30,7% |
17,2% |
|
25,4% |
11,1% |
|
|
Profit for the period |
646 944 |
302 166 |
114% |
1 019 323 |
319 596 |
219% |
|
% of total sales |
22,2% |
12,5% |
|
17,9% |
8,1% |
|
|
EBITDA[3] |
1 017 067 |
550 097 |
85% |
1 719 709 |
583 117 |
195% |
|
% of total sales |
34,9% |
22,8% |
|
30,3% |
14,8% |
|
[1] The data is derived from unaudited interim IFRS consolidated financial statements for the six months period ended 30 June 2005 and 2006.
[2] The data is derived from audited IFRS consolidated financial statements for 2004 and 2005.
[3] EBITDA is defined as profit for the period before income tax expense, finance costs, depreciation and amortisation.
|
.jpg){kind=small}
